New dawn of cannabinoid pharmacology.
Devane
W A
WA
Laboratory of Cell Biology, National Institute of Mental Health, Bethesda, MD 20892.
D000577:Amides / Q000494:pharmacology*; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D001095:Arachidonic Acids; D048588:Benzoxazines; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002186:Cannabinoids / Q000494:pharmacology; D063388:Endocannabinoids; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology*; D006801:Humans; D008024:Ligands; D009025:Morpholines / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D053284:Polyunsaturated Alkamides; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000187:drug effects*
D000577:Amides; D000700:Analgesics; D001095:Arachidonic Acids; D048588:Benzoxazines; D002121:Calcium Channel Blockers; D002186:Cannabinoids; D063388:Endocannabinoids; D005231:Fatty Acids, Unsaturated; D008024:Ligands; D009025:Morpholines; D009281:Naphthalenes; D053284:Polyunsaturated Alkamides; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; C078815:HU 243; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; C078814:anandamide